Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial.

Fiche publication

Date publication

mars 2025

Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr PEIGNAUX Karine , Dr DESMOULINS Isabelle , Dr BESSIERES Igor

Tous les auteurs :
Caluwé A, Bellal S, Cao K, Peignaux K, Remouchamps V, Baten A, Longton E, Bessieres I, Vu-Bezin J, Kirova Y, Gestel DV, Desmoulins I, Ignatiadis M, Romano E, Buisseret L, Piccart M, Vandekerkhove C, Gulyban A, Poortmans P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40057199

Résumé

The randomized multicentric phase II Neo-CheckRay trial investigated preoperative immune-modulating stereotactic body radiation therapy (iSBRT) 8 Gy x 3 fractions in combination with chemotherapy with or without the anti PD-L1 durvalumab and the anti-CD73 oleclumab in early-stage, high-risk, luminal B breast cancer. iSBRT was solely delivered to the primary breast cancer leveraging on its immune modulating potential to sustain an anti-tumour response. To avoid immunosuppression induced by radiation therapy (RT), the tumour draining lymph nodes (TDLN) were spared. Here, we present the constraints used in the Neo-CheckRay trial and a dosimetric analysis of all delivered treatment plans with a special focus on the dose to the TDLN.